Search Results for "free ce"

Elranatamab-bcmm, an immunotherapy indicated for relapsed or refractory multiple myeloma, received accelerated approval in 2023. It is a bispecific antibody and T-cell engager that binds to BCMA, which occurs on the surface of myeloma and other cells, and CD3, which occurs on T cells, causing cytokine release and myeloma cell lysis. This ONS resource was produced for educational purposes only. Refer to the full elranatamab-bcmm (Elrexfio™) package insert for all details.

Nurses are on the front lines of a global health emergency, riding the ebb and flow of uncertainty. We’ve struggled, lost, grieved, lifted up one another, and went inward to uncover strength we never thought we would need. Although we’ve longed to be together, we’ve experienced events and gatherings from behind a screen for the past two years.

Are you interested in the specialty of radiation oncology or already working in the field? Do you work in a large academic medical center, hospital, standalone radiation therapy facility, local urgent care, rural community area, or even a primary care office? Do you care for patients receiving specialized radiation or who have previously received radiation? Do you provide symptom management for patients experiencing acute or late side effects from radiation?  

The extra or missing chromosomes—also called aneuploidy—in 90% of cancer cells may be a factor in treatment resistance, a new study shows. Researchers reported the findings in Developmental Cell.

Rapid advancements in the science of chimeric antigen receptor (CAR) T-cell therapies present unique challenges and opportunities related to patient care. Nurses are at the forefront of those advancements—contributing to practice guidelines, developing center-specific protocols, publishing outcomes and best practices, and researching the patient experience, outcomes, and supportive interventions.